PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor.PI3K/Akt/mTOR-IN-2 has anticancer effects and is selective for MDA-MB-231 cells with an IC50 of 2.29 μM.PI3K/Akt/mTOR-IN-2 exhibits anticancer activity and induces cycle arrest and apoptosis in cancer cells. PI3K/Akt/mTOR-IN-2 has anticancer activity and can induce cycle arrest and apoptosis in cancer cells.

PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 h) demonstrates significant anti-cancer efficacy, with IC50 values ranging from 2.29 to 24.63 μM. Notably, its IC50 in MDA-MB-231 cells is 2.29 μM.[1]
PI3K/Akt/mTOR-IN-2 (1, 2 and 4 μM; 24 h) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.[1]
PI3K/Akt/mTOR-IN-2 (1, 2, and 4 μM; 24, 48, and 72 h) elicits apoptosis in MDA-MB-231 cells in a manner that is both dose- and time-dependent.[1]
PI3K/Akt/mTOR-IN-2 (1, 2, and 4 μM; 48 h) increases the expression of Bax and decreases the expression of Bcl-2 in MDA-MB-231 cells.[1]
PI3K/Akt/mTOR-IN-2 (1, 2, and 4 μM; 24 h) triggers mitochondria-dependent apoptosis in MDA-MB-231 cells by perturbing mitochondrial membrane potential (MMP), causing an increase in reactive oxygen species (ROS), reducing intracellular glutathione (GSH) levels, and elevating intracellular calcium ion (Ca2+).[1]